News | August 11, 2021
Lupin posts net profit of Rs 542.46 cr. in Q1FY22
The profits were bolstered by the Boehringer Ingelheim MEK program income
The profits were bolstered by the Boehringer Ingelheim MEK program income
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
This work has been published in the journal ‘ACS applied materials and interface’
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Filing for WHO Emergency Use Authorisation this month
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
Subscribe To Our Newsletter & Stay Updated
